Objective-CD98 regulates integrin signaling and is critical for tumor cell proliferation. It is also expressed on endothelial cells (EC), but its role in angiogenesis is unclear. Approach and Results-We used specific genetic targeting and antibody blockade approaches to examine the function of CD98 in EC proliferation, blood vessel growth, and tumor angiogenesis. It is upregulated on angiogenic ECs, and EC-specific deletion of CD98 in mice inhibited tumor growth, retinal angiogenesis, and EC proliferation. Reconstitution with CD98 mutants showed that integrin and CD98 interaction is necessary for EC survival and growth. Moreover, anti-CD98 treatment inhibited vessel formation and reversed EC-assisted tumor growth. 
A ngiogenesis is critical for many biological processes, including tumor growth, embryonic development, and wound healing. Antiangiogenic therapies have shown promise for cancer and other diseases. Angiogenesis depends on endothelial cell (EC) migration and proliferation and is directed by signaling through growth factor receptors and integrins. 1 Integrin signaling is directly regulated by interaction with tyrosine kinase receptors 2 and adaptor proteins.
3
CD98 is one integrin-interacting protein that governs the proliferation of multiple cell types, [4] [5] [6] but its role in ECs is unknown. It is a transmembrane heterodimer composed of a heavy chain (CD98hc, encoded by Slc3a2 in mice) and 1 of 6 light chains. 7 CD98hc is overexpressed on tumor cells and is the target of blocking reagents in clinical trials for human cancer.
Because CD98hc participates in integrin signaling and regulates rapid cell proliferation, we hypothesized a role for endothelial CD98hc in pathological and developmental angiogenesis. We tested this in mouse models and cell lines using genetic targeting and antibody blockade. We found that CD98hc is overexpressed on proliferative ECs, that this expression is essential for tumor growth and retinal angiogenesis in vivo, and that its integrinsignaling domain is required for EC growth. CD98hc blockade inhibited human umbilical vein endothelial cell (HUVEC) tube formation, reduced vascular endothelial growth factor receptor-2 (VEGFR-2) phosphorylation in response to VEGF, and inhibited EC-assisted tumor growth. These data establish an important role for CD98 in integrin-dependent signals that contribute to angiogenesis and raise the possibility of simultaneously inhibiting angiogenesis and tumor cell growth through CD98hc blockade.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

CD98hc Is Critical for Angiogenesis In Vivo
Growth factor receptor and integrin signaling are required for angiogenesis, 1,2 and CD98 mediates integrin signaling. 8, 9 We first observed that angiogenic endothelium (from B16 melanoma tumor) expressed ≈40% more surface CD98hc protein than EC from quiescent tissue ( Figure I in the online-only Data Supplement), indicating that CD98hc is upregulated on proliferative ECs during pathological angiogenesis. We thus investigated the requirement of CD98hc for tumor angiogenesis using a VE-Cad-CreER T2 Slc3a2 fl/fl mouse that deletes CD98hc (encoded by Slc3a2), on ECs after tamoxifen treatment. We found that EC-specific loss of CD98hc ( Figure 1A ) inhibited B16 tumor growth and resulted in tumors with ≈4-fold smaller mass ( Figure 1B ) and reduced vascular density ( Figure 1C ). Similar results were obtained using the Lewis lung carcinoma tumor model ( Figure II in the online-only Data Supplement). Together, these data indicate that CD98 expression on tumor ECs is necessary for efficient tumor growth. Because endothelial CD98 is important for tumor growth, we next tested whether it is specifically required for formation of new blood vessels in a mouse retinal angiogenesis model 10 
Integrin-Binding Domain of CD98hc Promotes EC Proliferation
CD98hc mediates amino acid transport and integrin signaling through distinct domains. The transmembrane and cytoplasmic regions of CD98hc are required to support integrin signaling, whereas the extracellular domain interacts with the light chain to transport amino acids. 8, 9 To identify CD98hc domain(s) critical for EC survival, we immortalized endothelial cells (imLEC) from Slc3a2 f/f mouse lung tissue. Genetic deletion of endogenous CD98hc in this cell line strongly impaired adhesion to β1 or β3 integrin ligands and caused imLEC death in 4 days (Figure 2A and 2B, top right). Reconstitution with full-length CD98hc or a CD98hc-CD69 domain-swapped chimera that retained CD98hc transmembrane and cytoplasmic domains rescued CD98hc-null imLECs from death, whereas full-length CD69 or the chimera lacking transmembrane CD98hc failed to rescue imLEC ( Figure 2B, right) . This demonstrates that the integrin signaling domain of CD98hc is essential for EC survival and proliferation.
CD98hc Blockade Inhibits Angiogenesis
Antibodies specific for CD98hc have direct effects on growth and survival of human tumor cells, 11 but their effects on human EC angiogenesis are unknown. Two days after incubating HUVEC with cross-linked anti-CD98hc antibody, the Tumors were harvested and collagenase digested from B16 melanoma-bearing mice on day 21 after tumor cell inoculation. ECs were enriched with CD31-coated beads and stained with antibodies for mouse CD98hc (or isotype control) on CD31 + CD102 + cells, followed by flow cytometry. B, Tumor growth after EC-specific CD98 deletion. B16 tumors were measured every 2 d beginning on day 7 (left). On day 18, mice were euthanized, and excised tumors weighed (right). Error bars=SEM for n=10 mice per group. *P<0.05 (1-tailed t test). C, Tumor vasculature. B16 tumor sections were stained for CD31; representative images are shown on left with summary quantification from >25 image fields on right. Scale bar=250 μm. D, Retinal angiogenesis. VE-Cad-CreER T2 Slc3a2 fl/fl and Slc3a2 fl/fl mice littermate mice were treated daily with tamoxifen on postnatal day 3 (P3) to P5 and euthanized on P10. Retinas were stained for CD98hc and blood vessels (isolectin B4); representative 2-channel close-up images of whole mount retinas with a ×20 objective are shown. Multiple retinal regions were computer-merged to create whole-mount images (E). Bar in (D)=50 μm; bar in (E)=500 μm. F, Retinal vessel coverage. Summary bar graph shows areas covered by blood vessel staining in merged images from (E) that were calculated using ImageJ software. Error bars are SEM for n=4 per group. level of surface CD98hc ( Figure 2C ) by flow cytometry and total CD98hc ( Figure 2E ) in cell lysates was significantly decreased as was the ability to form tube-like structures on Matrigel, a widely used model to study EC angiogenic activities in vitro ( Figure 2D ).
Crosstalk between integrin and tyrosine kinase receptors is an important mechanism for angiogenesis. 2 Because CD98hc mediates integrin signaling, we hypothesized that CD98hc could also regulate VEGFR-2 activation. To test this, we inhibited CD98hc and analyzed VEGFR-2 phosphorylation by VEGF as a measure of VEGFR-2 activation. Isotype-treated HUVEC strongly phosphorylated VEGFR-2 in response to VEGF stimulation, whereas anti-CD98hc pretreatment decreased CD98hc protein and partially inhibited VEGFstimulated VEGFR-2 phosphorylation ( Figure 2E ). To confirm the proposed mechanism that CD98 regulates VEGFR-2 signaling, we treated HUVEC with anti-CD98 antibody and found that this greatly reduced VEGF-stimulated cell spreading ( Figure IV in the online-only Data Supplement). Thus, CD98hc promotes VEGFR-2 signaling, which is crucial for angiogenesis.
To investigate the effects of CD98hc blockade on tumor angiogenesis in vivo, we injected B16 mouse melanoma cells alone on one hind flank, or in combination with HUVEC on the contralateral flank, of immunodeficient mice, followed by anti-CD98hc antibodies or isotype IgG. 12 In isotype controltreated mice, B16+HUVEC tumors grew significantly larger than B16 alone tumors ( Figure 2F, left) . In contrast, in mice receiving anti-CD98hc antibodies, HUVEC failed to increase B16 tumor growth ( Figure 2F, right) . This observation and our in vitro results using anti-CD98hc on HUVEC indicate that anti-CD98hc treatment can slow tumor growth by inhibiting human EC angiogenesis.
Discussion
Angiogenesis is an important biological process in inflammation, wound healing, embryonic development, and cancer. Integrin signaling, particularly from β3 and β1 integrins, is crucial for angiogenesis. 13, 14 CD98 is known to promote signaling from these integrins 9, 15, 16 and to activate pathways that have been implicated in angiogenesis. 17, 18 We have now shown that CD98hc is overexpressed on tumor ECs and that loss of endothelial CD98hc impairs tumor growth and angiogenesis. Genetic deletion of CD98hc and reconstitution with chimeras showed that the integrin-interacting domain of CD98hc is necessary and sufficient for EC survival and growth.
We also found that partial loss of CD98hc function through antibody blockade decreases HUVEC CD98hc protein expression and capillary tube formation. Consistent with these observations, VEGF-induced phosphorylation of VEGFR-2, a key player in angiogenesis, is partially inhibited by anti-CD98hc treatment, indicating a plausible mechanism whereby CD98hc regulates EC functions.
One possible application for anti-CD98hc reagents is to stop tumor growth by blocking angiogenesis. We found that administration of anti-(human)CD98hc antibody in mice abolishes HUVEC-assisted tumor growth. Approved clinical trials (NCT01516645 and NCT02040506) for anti-CD98 antibodies to treat human cancers suggest that low toxicity profiles were observed in preclinical data. Thus, our studies show that CD98 is required for developmental and pathological angiogenesis and suggest that CD98 inhibition may be a 2-pronged approach for tumor treatment.
